Testing a cancer vaccine plus immune therapy for hard tumors
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18–75, and you can likely live more than 3 months
- Your cancer is advanced or has returned, and a recent test shows EphA2 is high (at least 20%)
- Your tumor must have a specific TP53 mutation (R273H, R175H, R248Q, or R249S) from the last 6 months
- You must be able to have new tissue collected (biopsy/lymph node sample) or provide stored tumor tissue
- Your blood counts and organ tests (liver, kidneys, bone marrow) must meet study thresholds
- You cannot have certain exclusions like TP53 germline (inherited) mutation or uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a personalized cell therapy that uses your own immune cells, modified to target a specific genetic mutation found in some tumors. It aims to see if this treatment can shrink tumors or slow their growth in people with advanced cancer.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This study tests a new type of immune cell therapy that seeks out and attacks cancer cells. It is for people with advanced solid tumors who have not improved with standard treatments and whose tumors show certain markers.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.